TUKYSA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Seagen Inc.. The primary component is Tucatinib.
Product ID | 51144-001_74cd362f-e2e4-4f5d-8885-29f5a973e040 |
NDC | 51144-001 |
Product Type | Human Prescription Drug |
Proprietary Name | TUKYSA |
Generic Name | Tucatinib |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2020-04-17 |
Marketing Category | NDA / NDA |
Application Number | NDA213411 |
Labeler Name | SEAGEN INC. |
Substance Name | TUCATINIB |
Active Ingredient Strength | 50 mg/1 |
Pharm Classes | Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Tyrosine Kinase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2020-04-17 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA213411 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2020-04-17 |
Ingredient | Strength |
---|---|
TUCATINIB | 50 mg/1 |
NDC | Brand Name | Generic Name |
---|---|---|
51144-001 | TUKYSA | tucatinib |
51144-002 | TUKYSA | tucatinib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TUKYSA 88682720 not registered Live/Pending |
Seattle Genetics, Inc. 2019-11-06 |
TUKYSA 88209362 not registered Live/Pending |
Seattle Genetics, Inc. 2018-11-28 |